Dengue Fever Vaccine In Sight
A dengue fever vaccine created by Sanofi Pasteur has just entered Phase III trials, bringing the company closer to producing something that can prevent the disease than ever before.
Dengue is not as well-known or widespread as pervasive diseases like malaria, but it infects several million people a year. Although restricted to the tropics, it is growing in geography and today has the potential to infect several billion people, according to the World Health Organization.
The dengue fever vaccine is the latest in a long line of vaccines targeted at combating mosquito-borne illnesses, and Sanofi is placing a heavy bet that it will work. According to Reuters, Sanofi has invested over $400 million in making a manufacturing facility to create the vaccine in the event that it proves to be effective. Production would start in 2015 if all goes according to plan.
There are four other main competing vaccines but all are more unproven – in Phase I or II instead of Phase III trials like Sanofi’s – and so it would take around half a decade longer for them to come to market.
Creating a Dengue fever vaccine is complicated because there are 4 distinct types, all of which have to be accounted for in a vaccine, for it to be considered effective.
Keep Reading
Most Popular
A Roomba recorded a woman on the toilet. How did screenshots end up on Facebook?
Robot vacuum companies say your images are safe, but a sprawling global supply chain for data from our devices creates risk.
A startup says it’s begun releasing particles into the atmosphere, in an effort to tweak the climate
Make Sunsets is already attempting to earn revenue for geoengineering, a move likely to provoke widespread criticism.
10 Breakthrough Technologies 2023
These exclusive satellite images show that Saudi Arabia’s sci-fi megacity is well underway
Weirdly, any recent work on The Line doesn’t show up on Google Maps. But we got the images anyway.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.